For a patient needing an emergency brain drain, the minutes spent screwing a metal frame into their skull for surgical navigation are more than an inconvenience. They are a barrier to care, confining a delicate, life-saving procedure to a fully equipped operating room and a surgeon's steady hand. Zeta Surgical, a Boston-based company founded in 2018, is betting that much of that infrastructure is no longer necessary. Its core proposition is a navigation system that uses AI and computer vision, not physical markers, to guide a surgeon's tools with sub-millimeter accuracy. The goal is not just to improve precision, but to move the point of care [Perplexity Sonar Pro Brief].
This is a humane engineering problem. The company's technology, called RealTrack, continuously aligns a patient's pre-operative MRI or CT scan with their live facial anatomy, tracking movement 20 times per second [ZETA | Next-gen neuronavigation]. It promises the guidance of a $1 million intraoperative MRI suite from a compact, mobile cart. For William Gormley, a neurosurgeon at Mass General Brigham and the company's co-founder and chief medical officer, the clinical motivation is direct. "The commercial wedge is rapid deployment and lower setup friction," he noted in company materials, pointing out that their system for transcranial magnetic stimulation (TMS) can cut setup time to under two minutes [Perplexity Sonar Pro Brief].
The clinical evidence, so far
Peer-reviewed data is the currency of medical device adoption, and Zeta is building its case. In a clinical study for external ventricular drain (EVD) placement, a common emergency procedure to relieve pressure on the brain, the company reports its Zeta Cranial Navigation System achieved 100% ideal catheter placement on the first pass. That compared to an 81% success rate for the traditional freehand technique. Perhaps more telling for patient outcomes, the study reported a 0% rate of revision surgeries and adverse events in the navigated group, versus 19% and 28% respectively in the freehand cohort [ZETA | Next-gen neuronavigation].
These are early but compelling numbers for a specific procedure. They underscore the potential impact of bringing consistent, image-guided precision to settings where it was previously impractical or too slow. The system is now FDA 510(k) cleared for a growing list of indications, including brain tumor biopsies, hydrocephalus, and trigeminal neuralgia [ZETA SURGICAL® Receives FDA 510(k) Clearance Expanding Access to Brain Tumor Biopsies, Hydrocephalus, and Trigeminal Neuralgia, May 2026].
A dual-path commercial strategy
Zeta's commercial path unfolds across two related but distinct landscapes: the hospital and the outpatient clinic. Its original focus, the Zeta Navigation System, targets minimally invasive cranial procedures in operating rooms and emergency settings. The more recent regulatory win is for the Zeta TMS Robotic System, which received FDA 510(k) clearance in July 2026 [Yahoo Finance, July 2026]. This system automates the positioning of coils for transcranial magnetic stimulation, a non-invasive therapy for major depressive disorder and other conditions.
| Product System | Primary Setting | Key Differentiator | FDA Status |
|---|---|---|---|
| Zeta Cranial Navigation System | Hospitals, Emergency Departments | Markerless, real-time guidance for procedures like EVD placement | 510(k) Cleared [Medical Device Developments, retrieved 2026] |
| Zeta TMS Robotic System | Outpatient Psychiatry & Neurology Clinics | Submillimeter robotic coil positioning for depression treatment | 510(k) Cleared (July 2026) [Yahoo Finance, July 2026] |
The TMS clearance opens a potentially faster route to revenue. While selling capital equipment into hospital neurosurgery departments is a long-cycle game, outpatient TMS clinics are commercial businesses hungry for efficiency and differentiation. Zeta announced its first commercial deployment at a HOPE Therapeutics clinic in 2026 [PR Newswire, June 2026]. With a team of just 13 people, the company reportedly reached $2 million in revenue in 2024, suggesting its capital-light model and focused sales are gaining traction [How Zeta Surgical hit $2M revenue with a 13 person team in 2024, retrieved 2026].
The team behind the bet
The founding trio brings a blend of technical and clinical credibility that resonates in medtech. CEO José María Amich and CTO Raahil Sha are Harvard graduates who started the company as classmates. They provide the engineering and product vision. Dr. William Gormley anchors the effort in clinical reality, practicing at Mass General Brigham and serving as Director of Neurosurgical Innovation there [Perplexity Sonar Pro Brief]. This hospital affiliation has been crucial for early development and studies. The founders' academic work on frameless neuronavigation has been published, and Amich and Sha were named to the Forbes 30 Under 30 list in 2024 [Mr. Jose Maria Amich | Author | University of Cambridge, retrieved 2026] [Zhi Wang - LinkedIn, retrieved 2026].
Financing has come from a mix of institutional and angel investors. The company emerged from stealth in March 2022 with a $5.2 million seed round led by Innospark Ventures, with participation from TSVC, Y Combinator, Plug and Play Ventures, and former Tenet Healthcare CEO Trevor Fetter [TechCrunch, March 2022]. Total disclosed funding is approximately $7 million [Perplexity Sonar Pro Brief, 2023]. The relatively modest raise for a hardware-software medtech company hints at a lean operational approach, consistent with the small team size.
Navigating a crowded and regulated field
The market for surgical navigation is not greenfield. Zeta faces established giants like Medtronic and Brainlab, which dominate the traditional operating-room navigation market with deeply integrated suites. Its wedge is not to out-feature them in the OR, but to enable procedures outside their core domain. The risk is that these incumbents could develop or acquire similar markerless technology for the bedside, leveraging their vast sales forces and existing customer relationships.
The company's most plausible answer is speed and focus. By targeting specific, high-value procedures like EVD placement and navigated TMS, Zeta can build a beachhead with clinical evidence and a reputation for solving acute workflow problems. Its recent FDA clearance for network integration, allowing hospitals to plug the system into their IT infrastructure for easier data access, is a small but critical step toward the smooth integration that hospitals demand [Medical Device Developments, retrieved 2026].
Furthermore, the regulatory path itself is a moat. Each new 510(k) clearance expands the labeled indications for use, creating a cumulative barrier. The recent clearance for the TMS robot, specifically, places Zeta in a sparser competitive field where its surgical-grade accuracy is a novel selling point for psychiatric care.
What standard of care looks like today
For the patient populations Zeta serves, the current standard of care involves a trade-off between precision and accessibility. In neurosurgery, accurate placement of a drain or biopsy needle often requires a stereotactic frame fixed to the patient's skull, a process that is time-consuming, uncomfortable, and typically demands general anesthesia. In outpatient TMS therapy, coil placement is usually done manually using anatomical landmarks, a method susceptible to human error and patient movement, which can affect treatment efficacy.
Zeta's ambition is to erase that trade-off. The promise is that a neurosurgeon in a community hospital emergency room, or a technician in a storefront TMS clinic, can achieve a level of accuracy that was once the exclusive domain of major academic medical centers. The next twelve months will test how well that promise converts into commercial rhythm. Key milestones to watch include published outcomes from the first commercial TMS sites, the announcement of a first major hospital system deal for the cranial platform, and likely, a new funding round to scale manufacturing and sales as the product portfolio expands.
Sources
- [Perplexity Sonar Pro Brief] Zeta Surgical company overview and product description
- [ZETA | Next-gen neuronavigation] Company website detailing technology and clinical study results
- [TechCrunch, March 2022] Zeta Surgical comes out of stealth with a $5.2M raise for image-guided surgery | https://techcrunch.com/2022/03/10/zeta-surgical-comes-out-of-stealth-with-a-5-75m-raise-for-image-guided-surgery/
- [Medical Device Developments, retrieved 2026] Report on FDA clearance for network integration
- [Yahoo Finance, July 2026] Report on FDA 510(k) clearance for Zeta TMS Robotic System
- [PR Newswire, June 2026] ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics
- [How Zeta Surgical hit $2M revenue with a 13 person team in 2024, retrieved 2026] Article on company revenue and team size
- [ZETA SURGICAL® Receives FDA 510(k) Clearance Expanding Access to Brain Tumor Biopsies, Hydrocephalus, and Trigeminal Neuralgia, May 2026] Company press release
- [Mr. Jose Maria Amich | Author | University of Cambridge, retrieved 2026] Academic publication reference for founders
- [Zhi Wang - LinkedIn, retrieved 2026] Post noting Forbes 30 Under 30 recognition